Cell Biosciences Nabs $20M, Buys Convergent

Xconomy San Francisco — 

Cell Biosciences, a Santa Clara, CA-based maker of life sciences instruments, supplies and software, said it has raised $20 million in a Series F venture round in connection with a $12 million acquisition of Toronto, Canada-based Convergent Bioscience. The investment was led by Essex Woodlands Health Ventures, and included existing investors such as The Wellcome Trust, Novo A/S, Domain Associates, Latterell Venture Partners, Royal Bank of Canada, The Vertical Group, and Lansing Brown Investments. Convergent, founded in 1995, has 45 employees.